查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370965

再生醫學市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按治療、材料、按應用、最終用戶、地區和競爭細分

Regenerative Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Therapy, By Material, By Application, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球再生醫學市場價值為 146.7 億美元，預計在整個預測期內將實現強勁成長，年複合成長率 (CAGR) 為 9.45%，預計到 2028 年將達到 251.1 億美元。再生醫學、一個新興領域，專注於替換或修復受損的人體器官或組織。這種治療方法採用幹細胞來恢復缺乏自癒能力的器官和組織的功能。科學家預見在實驗室中培育器官和組織的潛力，然後可以安全地移植到人體中。對再生醫學的需求不斷成長是由於其個人化治療方法，與傳統方法相比，它可以提供更有效的疾病管理。這涵蓋了多種醫療技術，包括人造器官、細胞療法和組織工程。組織工程和生物材料使用植入支架來促進新組織的形成，吸引幹細胞以促進具有所需特性的組織發育。細胞療法利用各種來源的幹細胞來修復受損的組織。此外，醫療設備和人造器官為患病器官提供支援。

主要市場促進因素

增加對研發 (R&D) 活動的投資

市場概況
預測期 2024-2028
2022 年市場規模 146.7億美元
2028 年市場規模 251.1億美元
2023-2028 年年複合成長率 9.45%
成長最快的細分市場 組織工程
最大的市場 北美洲

不斷成長的研發投資透過促進創新產品的推出推動了市場擴張。投資的增加催生了全面的研發計劃，許多新創公司為新療法和產品獲得了資金。這促進了旨在最佳化研發活動效益的實質合作、合併和夥伴關係。 2022年6月，比利時生物技術公司Galapagos收購了Cell Point和Abound Bib，這是一項旨在加速先進細胞療法的開發和商業化的策略性舉措。透過整合 Cell Point 和 Abound Bio，Galapagos 獲得了創新、可擴展、分散和自動化的照護端細胞治療供應模式，以及尖端的全人類抗體治療平台。這些進步使 Galapagos 成為一家綜合生物製藥公司，有可能顛覆 CAR-T 治療模式。除了私人實體之外，各國政府和政府資助的研究機構也積極投資該產業，為癌症、帕金森氏症、糖尿病、腎臟疾病、心血管疾病等慢性疾病引入有效的治療方案。 2022 年 1 月，愛爾蘭皇家外科學院從歐盟委員會獲得了 226,000 美元的資金，用於開發用於骨質疏鬆症骨治療的抗氧化劑離子替代奈米顆粒。

慢性病盛行率增加

心臟病、糖尿病和癌症等慢性疾病的發生率上升預計將推動市場成長。例如，美國疾病管制與預防中心的資料顯示，美國有 3,730 萬人患有糖尿病。導致糖尿病激增的因素包括生活方式的改變、人口老化和體力活動不足。幹細胞生物學利用各種幹細胞類型（包括胚胎細胞、種系細胞、間質細胞和誘導多能細胞）為糖尿病治療提供了一個有前景的途徑。

遺傳性疾病和創傷緊急情況的發生率不斷上升

充血性心臟衰竭、心肌梗塞、帕金森氏症、各種形式的骨質流失和杜氏肌肉營養不良症（DMD）等疾病的日益流行正在推動再生醫學市場對細胞療法的需求。此外，對膀胱、輸尿管和尿道重建的自體移植物的依賴也推動了市場的成長。許多公司正在透過合作推進細胞療法。例如，禮來公司於 2018 年 4 月與 Sigilon Therapeutics 合作開發用於治療 I 型糖尿病的封裝細胞療法。此類尖端產品的推出將推動細胞療法的需求並促進再生醫學市場的發展。雖然自體、同種異體和異種細胞療法廣泛應用於再生醫學市場，但只有有限數量的產品獲得 FDA 商業化批准。例如，Fibrocell Science, Inc.的Laviv被批准用於治療成人中度至重度鼻唇溝皺紋，而Genzyme Corporation的Carticel則用於修復膝蓋的症狀性軟骨缺損。創傷的普遍存在促進了再生醫學和器官移植的採用。事故、燒傷和其他創傷病例的增加極大地提振了再生醫學市場。根據疾病管制與預防中心的數據，2019 年，與創傷性腦損傷(TBI) 相關的住院人數約為223,135 人，2021 年，有69,473 人因TBI 相關死亡。這些數字相當於超過611 人因TBI 相關住院，176 人因TBI 死亡在美國每天。事故創傷病例的激增推動了全球對再生藥物的需求。儘管許多公司已擴展到創傷損傷的再生醫學市場，但該領域仍主要用於器官移植。然而，事故護理技術的進步預計將導致預測期內再生醫學市場的快速成長。

新技術的出現

3D 列印等新技術的出現預計將推動自體細胞療法在危及生命的情況下的採用。 Organogenesis, Inc. 開發的 Apligraf 等著名產品利用同種異體細胞治療潰瘍。再生技術的進步推動了幹細胞在市場上的應用。心臟動脈、工程膀胱和其他內部結構等器官的創新有助於這項進步。目前許多基於幹細胞的療法正在進行臨床試驗，顯示出組織再生的巨大潛力。市場參與者推出了多項技術來提高幹細胞研究效率和商業應用，從而刺激再生醫學市場的成長。政府和私人機構的研發計劃和投資預計將在預測期內支持市場成長。然而，與再生醫學治療相關的高成本可能會對市場擴張構成障礙。葛蘭素史克的腺苷脫氨酶產品會導致嚴重聯合免疫缺陷(ADA-SCID)，而其他公司的基因附加療法研究，包括GE Healthcare 和Mayo Clinic，則採用鋅指核酸酶(ZFN)、CRISPR /Cas9 和mega 核酸酶等核酸酶（MN）修改人類基因組。然而，基因校正可能會對細胞發育和增殖產生意想不到的影響。此外，基因校正治療的效率會根據目標細胞的基因組而變化，限制了其應用。

主要市場挑戰

用於細胞和基因治療的載體生產不足

目前的向量生成方法通常缺乏可擴展性。滿足臨床試驗和商業化需求可能具有挑戰性，特別是針對大量患者群體的治療。隨著再生醫學的進步，治療方法多樣化，需要可靠的載體生產方法來生產各種載體，包括腺相關病毒 (AAV) 和慢病毒。

治療費用高

使用這些產品的治療成本高昂，加上缺乏報銷政策，阻礙了市場的成長。大多數幹細胞療法被歸類為實驗性或研究性治療，導致醫療保險覆蓋範圍有限，並需要大量自付費用。醫療保險專門承保 FDA 批准的療法（例如同種異體移植）的費用。幹細胞治療的費用差異很大，從 5,000 美元到 50,000 美元不等，受細胞類型、數量、品質和來源等因素的影響。例如，諾華公司的Zolgensma，一種治療脊髓性肌肉萎縮症的拋棄式基因療法，售價為212萬美元。由於缺乏保險覆蓋，患者必須自掏腰包支付治療費用或訴諸眾籌，從而延誤治療並阻礙市場成長。此外，針對各種遺傳性疾病的核准療法的可用性有限，通常伴隨著高昂的費用和潛在的副作用，進一步限制了它們的採用和市場成長。

主要市場趨勢

新興經濟體的潛力不斷成長

在全球創傷性損傷和器官移植發生率不斷上升的推動下，發展中經濟體在再生醫學市場上呈現巨大的潛力。主要產業參與者策略性地認知到這些經濟體中組織工程和再生醫學的機會，利用產品發布、批准、協議、合作夥伴關係和合併等策略。儘管由於不利的規範而面臨倫理挑戰，但發展中經濟體預計將採用組織工程和再生技術。

器官移植領域對再生醫學的需求不斷成長

腎臟移植需求量大，等待名單中 80% 是腎臟病患者。儘管政府努力增加捐贈者數量，但對器官移植的需求仍在持續增加。組織工程和再生醫學在滿足全球移植需求方面具有巨大潛力。必須克服血管形成和組織訊號傳導等挑戰才能成功複製原始器官功能。利用組織工程、再生和生物列印技術開發複雜組織甚至整個器官方面取得了明顯的進展。鑑於處於不同臨床試驗階段的眾多產品為未來的商業可用性做好了準備，再生醫學產品的商業化前景廣闊。

細分市場洞察

治療趨勢

2022年，組織工程將主導全球再生醫學市場，佔據最大的市場佔有率。諸如用功能性生活結構取代有缺陷的結構的能力以及治療以前無法治療的病症的潛力等優勢促成了這種優勢。大量的研發投資和持續的創新產品推出預計將推動組織工程領域的需求。

應用洞察

由於全球癌症負擔不斷增加，腫瘤學將在 2022 年引領再生醫學市場。政府和私營部門對癌症研究和先進細胞療法開發的投資發揮了關鍵作用。 2023 年 1 月，Calidi Biotherapeutics (CBT) 和 First Light Acquisition Group (FLAG) 聯手使用基於幹細胞的平台徹底改變溶瘤病毒療法。在細胞療法和再生醫學進步的推動下，心血管領域預計將顯著成長。主要參與者積極開發用於修復、恢復和重建受損心臟組織的再生療法。採用自體和異體單細胞和混合細胞來研究其對心血管疾病的影響的情況正在增加。此外，還研究了生物製劑、小分子和基因療法用於再生心臟細胞，進一步推動市場成長。

區域洞察

從地理上看，由於慢性病的高盛行率和先進的醫療基礎設施，北美在再生醫學市場佔據主導地位。相較之下，在醫療保健支出增加以及主要製造商在推出新產品方面進行大量投資的推動下，亞太地區有望快速成長。隨著療法進入臨床試驗第三階段，北美再生醫學市場正處於成長階段，未來潛力巨大。這顯示出積極的商業化努力。組織工程的有利監管和報銷政策表明政府有興趣支持再生產品的成長。然而，主要出於倫理考慮，與幹細胞技術相關的嚴格監管政策阻礙了胚胎幹細胞的採用，為市場成長帶來了挑戰。

目錄

第 1 章：治療概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球再生醫學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療（幹細胞治療、基因治療、組織工程以及小分子和生物療法）
    • 依材料（合成材料、生物衍生材料、基因工程材料及藥品）
    • 按應用（心血管、腫瘤、肌肉骨骼、傷口癒合、眼科等）
    • 按最終用戶（醫院、專科中心、學術和研究機構）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美再生醫學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過治療
    • 按材質
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲再生醫學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過治療
    • 按材質
    • 按應用
    • 按最終用戶
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區再生醫學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過治療
    • 按材質
    • 按應用
    • 按最終用戶
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲再生醫學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過治療
    • 按材質
    • 按應用
    • 按最終用戶
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲再生醫學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過治療
    • 按材質
    • 按應用
    • 按最終用戶
  • MEA：國家分析
    • 南非再生醫學
    • 沙烏地阿拉伯再生醫學
    • 阿拉伯聯合大公國再生醫學

第 11 章：市場動態

第 12 章：市場趨勢與發展

第 13 章：全球再生醫學市場：SWOT 分析

第14章：競爭格局

  • 商業概覽
  • 服務產品
  • 最近的發展
  • 主要人員
  • SWOT分析
    • Stryker Corporation
    • Athersys, Inc.
    • Integra Lifesciences Corporation
    • Isto Biologics (Isto Biologics Medical Systems, Inc.)
    • Organogenesis Inc.
    • CryoLife, Inc.
    • Medtronic plc
    • US Stem Cell, Inc.
    • Zimmer Biomet Holdings, Inc.
    • 3M Company

第 15 章：策略建議

第 16 章：關於我們與免責聲明

簡介目錄
Product Code: 4685

The Global Regenerative Medicine Market was valued at USD 14.67 Billion in 2022 and is projected to experience robust growth throughout the forecast period, with a Compound Annual Growth Rate (CAGR) of 9.45% and expected to reach USD 25.11 Billion through 2028. Regenerative medicine, an emerging field, concentrates on the replacement or repair of damaged human organs or tissues. Stem cells are employed in this therapeutic approach to restore function to organs and tissues that lack the ability to self-heal. Scientists foresee the potential for growing organs and tissues in laboratories, which can then be safely transplanted into the human body. The escalating demand for regenerative medicine is due to its personalized treatment approach, offering more effective disease management compared to conventional methods. This encompasses a variety of medical techniques including artificial organs, cellular therapies, and tissue engineering. Tissue engineering and biomaterials use implanted scaffolds to facilitate the creation of new tissue, attracting stem cells to foster tissue development with desired characteristics. Cellular therapies employ stem cells from various sources to repair damaged tissues. Moreover, medical devices and artificial organs provide support to ailing organs.

Key Market Drivers

Increasing Investments in Research and Development (R&D) Activities

Market Overview
Forecast Period2024-2028
Market Size 2022USD 14.67 Billion
Market Size 2028USD 25.11 Billion
CAGR 2023-20289.45%
Fastest Growing SegmentTissue Engineering
Largest MarketNorth America

Growing investments in R&D have driven market expansion by fostering innovative product launches. This uptick in investment has led to comprehensive R&D initiatives, with numerous start-up companies securing funding for novel therapies and products. This has facilitated substantial collaborations, mergers, and partnerships geared towards optimizing the benefits of R&D activities. In June 2022, Belgian biotech company Galapagos acquired Cell Point and Abound Bib, a strategic move aimed at accelerating the development and commercialization of advanced cell therapies. By integrating Cell Point and Abound Bio, Galapagos gains access to innovative, scalable, decentralized, and automated point-of-care cell therapy supply models, along with a cutting-edge fully human antibody-based therapeutics platform. These advancements position Galapagos as an integrated biopharmaceutical firm with the potential to disrupt the CAR-T treatment paradigm. Beyond private entities, various governments and government-funded research institutions are actively investing in this industry to introduce effective treatment options for chronic diseases like cancer, Parkinson's disease, diabetes, renal diseases, cardiovascular diseases, and others. In January 2022, the Royal College of Surgeons in Ireland secured USD 226,000 in funding from the European Commission for the development of antioxidant-ion substituted nanoparticles for osteoporotic bone treatment.

Increasing Prevalence of Chronic Conditions

The rising occurrence of chronic conditions like heart disease, diabetes, and cancer is expected to propel market growth. For example, data from the Centers for Disease Control and Prevention reveals that 37.3 million individuals in the United States are living with diabetes. Contributing factors to the diabetes surge include changing lifestyles, an aging population, and insufficient physical activity. Stem cell biology offers promising avenues for diabetes treatment, employing various stem cell types including embryonic, germline, mesenchymal, and induced pluripotent cells.

Growing Incidence of Genetic Disorders and Trauma Emergencies

The increasing prevalence of diseases such as congestive heart failure, myocardial infarction, Parkinson's disease, various forms of bone loss, and Duchenne muscular dystrophy (DMD) is driving the demand for cell therapy in the regenerative medicine market. Additionally, reliance on autologous grafts for bladder, ureter, and urethra reconstruction fuels market growth. Numerous companies are pushing forward with cell therapy through collaborations. For instance, Eli Lilly partnered with Sigilon Therapeutics in April 2018 to develop encapsulated cell therapies for type I diabetes treatment. The introduction of such cutting-edge products is poised to drive demand for cell therapies and boost the regenerative medicine market. While autologous, allogenic, and xenogenic cell therapies are widely used in the regenerative medicine market, only a limited number of products have received FDA approval for commercialization. For instance, Laviv from Fibrocell Science, Inc. is approved for treating moderate-to-severe nasolabial fold wrinkles in adults, while Carticel from Genzyme Corporation is used for symptomatic cartilage defect repair in the knees. The prevalence of trauma injuries has contributed to increased adoption of regenerative medicine and organ transplantation. The rise in accidents, burn injuries, and other trauma cases has significantly bolstered the regenerative medicine market. According to the Center for Disease Control and Prevention, Traumatic Brain Injury (TBI)-related hospitalizations reached approximately 223,135 in 2019, with 69,473 TBI-related deaths in 2021. These figures equate to over 611 TBI-related hospitalizations and 176 TBI-related deaths per day in the United States. This surge in accident trauma cases has driven global demand for regenerative medicines. While many companies have expanded into the regenerative medicine market for trauma injuries, this segment is still primarily used in organ transplantation. However, advancements in accident care technologies are expected to lead to rapid growth in the regenerative medicine market during the forecast period.

Emergence of New Technologies

The emergence of novel technologies such as 3D printing is expected to drive the adoption of autologous cell therapies for life-threatening conditions. Notable products like Apligraf, developed by Organogenesis, Inc., utilize allogenic cells for treating ulcers. Regenerative technologies' progress fuels stem cell applications in the market. Innovations in organs like heart arteries, engineered bladders, and other internal structures contribute to this advancement. Numerous stem cell-based therapies are currently undergoing clinical trials, demonstrating substantial potential for tissue regeneration. Market players have introduced several technologies to enhance stem cell research efficiency and commercial applications, thereby stimulating the growth of the regenerative medicine market. Government and private agency R&D programs and investments are expected to support market growth in the forecast period. However, the high costs associated with regenerative medicine treatments could pose a barrier to market expansion. GlaxoSmithKline's product for adenosine deaminase, which causes severe combined immunodeficiency (ADA-SCID), and other companies' gene additive therapies research, including GE Healthcare and Mayo Clinic, employ nucleases like zinc finger nucleases (ZFNs), CRISPR/Cas9, and mega nucleases (MNs) to modify the human genome. However, gene correction can have unintended effects on cell development and proliferation. Additionally, the efficiency of gene correction treatment varies depending on the targeted cells' genome, limiting its application.

Key Market Challenges

Insufficient Vector Production for Cell and Gene Therapy

Current vector production methods often lack scalability. Meeting clinical trial and commercialization demands can be challenging, particularly for therapies targeting large patient populations. As regenerative medicine advances, therapeutic approaches diversify, necessitating reliable vector production methods for various vectors, including adeno-associated viruses (AAVs) and lentiviruses.

High Treatment Costs

The high costs associated with treatments employing these products, coupled with the absence of reimbursement policies, hinder market growth. Most stem cell therapies are categorized as experimental or investigational treatments, leading to limited Medicare insurance coverage and significant out-of-pocket expenses. Medicare exclusively covers expenses for FDA-approved therapies such as allogeneic transplantation. Stem cell therapy costs vary widely, ranging from USD 5,000 to USD 50,000, influenced by factors such as cell type, quantity, quality, and source. For instance, Novartis' Zolgensma, a one-time gene therapy for spinal muscular atrophy, carries a price tag of USD 2.12 million. The lack of insurance coverage leaves patients to cover treatment costs out-of-pocket or resort to crowdfunding, delaying treatment and impeding market growth. Additionally, the availability of approved therapies for various genetic disorders is limited, often accompanied by significant expenses and potential side effects, further constraining their adoption and market growth.

Key Market Trends

Growing Potential in Emerging Economies

Developing economies present substantial potential in the regenerative medicine market, driven by the increasing incidence of traumatic injuries and organ transplants worldwide. Key industry players strategically recognize opportunities in tissue engineering and regenerative medicine within these economies, leveraging tactics such as product launches, approvals, agreements, partnerships, and mergers. Despite ethical challenges due to unfavorable norms, developing economies are anticipated to embrace tissue engineering and regeneration technology.

Rising Demand for Regenerative Medicine in Organ Transplantation

Kidney transplants are in high demand, with 80% of the waiting list comprising kidney patients. Despite government efforts to increase donor numbers, the demand for organ transplants continues to rise. Tissue engineering and regenerative medicine hold significant potential to address this global demand for transplants. Challenges like vascularization and tissue signaling must be overcome to replicate original organ functions successfully. Progress is evident in the development of complex tissues and even whole organs using tissue engineering, regeneration, and bioprinting technologies. Commercializing regenerative medicine products holds promise, given numerous products in various clinical trial phases, poised for future commercial availability.

Segment Insights

Therapeutic Trends

Tissue engineering dominated the global regenerative medicine market in 2022, claiming the largest market share. Advantages such as the ability to replace faulty structures with functional living counterparts and the potential to treat previously untreatable conditions contribute to this dominance. Significant R&D investments and ongoing innovative product launches are expected to drive demand in the tissue engineering segment.

Application Insights

Oncology led the regenerative medicine market in 2022 due to the growing global cancer burden. Government and private sector investments in cancer research and advanced cell therapy development played a pivotal role. In January 2023, Calidi Biotherapeutics (CBT) and First Light Acquisition Group (FLAG) joined forces to revolutionize oncolytic virotherapies using stem cell-based platforms. The cardiovascular segment is projected to experience notable growth, fueled by advancements in cell-based therapies and regenerative medicine. Key players actively develop regenerative therapies for repairing, restoring, and revascularizing damaged heart tissues. The adoption of autologous and allogeneic single and mixed cells for studying their effects on cardiovascular diseases is on the rise. Additionally, biologics, small molecules, and gene therapy are investigated for regenerating heart cells, further driving market growth.

Regional Insights

Geographically, North America dominates the regenerative medicine market due to the high prevalence of chronic diseases and advanced healthcare infrastructure. In contrast, the Asia-Pacific region is poised for rapid growth, driven by increased healthcare spending and significant investments by major manufacturers in introducing new products. North America's regenerative medicine market is in a growth phase with potential for the future, as therapies advance to the third phase of clinical trials. This indicates active commercialization efforts. Favorable regulatory and reimbursement policies for tissue engineering demonstrate government interest in supporting regenerative product growth. However, strict regulatory policies related to stem cell technologies, primarily due to ethical concerns, hamper the adoption of embryonic stem cells, posing challenges to market growth.

Key Market Players

  • Stryker Corporation
  • Athersys, Inc.
  • Integra Lifesciences Corporation
  • Isto Biologics (Isto Biologics Medical Systems, Inc.)
  • Organogenesis Inc.
  • CryoLife, Inc.
  • Medtronic plc
  • U.S. Stem Cell, Inc.
  • Zimmer Biomet Holdings, Inc.
  • 3M Company

Report Scope:

In this report, the Global Regenerative Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Regenerative Medicine Market, By Therapy:

  • Stem Cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Small Molecule & Biologic

Regenerative Medicine Market, By Material:

  • Synthetic Material
  • Biologically Derived Material
  • Genetically Engineered Material
  • Pharmaceuticals

Regenerative Medicine Market, By Application:

  • Cardiovascular
  • Oncology
  • Musculoskeletal
  • Wound Healing
  • Ophthalmology
  • Others

Regenerative Medicine Market, By End User:

  • Hospitals
  • Specialty Centres
  • Academic & Research Institutes

Regenerative Medicine Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Regenerative Medicine Market.

Available Customizations:

  • Global Regenerative Medicine market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Therapy Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Regenerative Medicine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy (Stem Cell Therapy, Gene Therapy, Tissue Engineering, And Small Molecule & Biologic)
    • 5.2.2. By Material (Synthetic Material, Biologically Derived Material, Genetically Engineered Material, And Pharmaceuticals)
    • 5.2.3. By Application (Cardiovascular, Oncology, Musculoskeletal, Wound Healing, Ophthalmology, And Others)
    • 5.2.4. By End User (Hospitals, Specialty Centres, Academic & Research Institutes)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map

6. North America Regenerative Medicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy
    • 6.2.2. By Material
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Regenerative Medicine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy
        • 6.3.1.2.2. By Material
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Regenerative Medicine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy
        • 6.3.2.2.2. By Material
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Regenerative Medicine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy
        • 6.3.3.2.2. By Material
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Regenerative Medicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Material
    • 7.2.3. By Application
    • 7.2.4. By End User
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Regenerative Medicine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By Material
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Regenerative Medicine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By Material
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Regenerative Medicine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By Material
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. France Regenerative Medicine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy
        • 7.3.4.2.2. By Material
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Regenerative Medicine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy
        • 7.3.5.2.2. By Material
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia-Pacific Regenerative Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Material
    • 8.2.3. By Application
    • 8.2.4. By End User
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Regenerative Medicine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Material
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Regenerative Medicine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Material
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Regenerative Medicine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Material
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Regenerative Medicine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By Material
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Regenerative Medicine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By Material
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. South America Regenerative Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Material
    • 9.2.3. By Application
    • 9.2.4. By End User
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Regenerative Medicine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Material
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Regenerative Medicine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Material
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Regenerative Medicine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Material
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. Middle East and Africa Regenerative Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Material
    • 10.2.3. By Application
    • 10.2.4. By End User
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Regenerative Medicine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Material
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Regenerative Medicine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Material
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Regenerative Medicine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Material
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

12. Market Trends & Developments

13. Global Regenerative Medicine Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Services Offerings
  • 14.3. Recent Developments
  • 14.4. Key Personnel
  • 14.5. SWOT Analysis
    • 14.5.1. Stryker Corporation
    • 14.5.2. Athersys, Inc.
    • 14.5.3. Integra Lifesciences Corporation
    • 14.5.4. Isto Biologics (Isto Biologics Medical Systems, Inc.)
    • 14.5.5. Organogenesis Inc.
    • 14.5.6. CryoLife, Inc.
    • 14.5.7. Medtronic plc
    • 14.5.8. U.S. Stem Cell, Inc.
    • 14.5.9. Zimmer Biomet Holdings, Inc.
    • 14.5.10. 3M Company

15. Strategic Recommendations

16. About Us & Disclaimer